MELROSEWAKEFIELD HEALTHCARE INC
1. Target Overview & Investment Thesis
MELROSEWAKEFIELD HEALTHCARE INC is a 160-bed under-performing / distressed in MIDDLESEX, MA with $217.5M in net patient revenue and a -42.6% operating margin. The hospital serves a payer mix of 38.9% Medicare, 5.9% Medicaid, and 55.2% commercial.
Thesis: Undervalued. Our ML models identify $16.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -42.6% to -35.2% (+736bps).
| Net Revenue HCRIS | $217.5M |
| Current EBITDA COMPUTED | $-92.6M |
| Operating Margin COMPUTED | -42.6% |
| Occupancy HCRIS | 60.2% |
| Revenue / Bed COMPUTED | $1.4M |
| Net-to-Gross HCRIS | 43.7% |
| Distress Probability ML | 48.2% |
2. Market Context & Competitive Position
MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -42.6% places it below the state median. Among 56 size-comparable peers (80-320 beds), the median margin is -10.1%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (80-320), prioritizing same-state peers. 56 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| MELROSEWAKEFIELD HEALTHCARE I (Target) | MA | 160 | $217.5M | -42.6% |
| NEWTON WELLESLEY HOSPITAL | MA | 216 | $624.3M | -4.7% |
| CAPE COD HOSPITAL | MA | 239 | $620.3M | -1.3% |
| BERKSHIRE MEDICAL CENTER | MA | 238 | $522.9M | -12.9% |
| NORTH SHORE MEDICAL CENTER | MA | 268 | $503.5M | -12.9% |
| STEWARD ST. ELIZABETHS MEDICAL | MA | 244 | $428.5M | 0.7% |
| BEVERLY HOSPITAL | MA | 261 | $410.6M | -1.6% |
| SAINT VINCENT HOSPITAL | MA | 232 | $404.2M | 0.2% |
| CAMBRIDGE HEALTH ALLIANCE | MA | 225 | $383.9M | -50.0% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $16.0M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $4.6M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $4.3M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $4.3M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $2.6M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $139K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-92.6M |
| + RCM Uplift | +$16.0M |
| Pro Forma EBITDA | $-76.6M |
| Current Margin | -42.6% |
| Pro Forma Margin | -35.2% |
| WC Released (1x) | $8.3M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-142.4M | $-450.5M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-142.4M | $-541.8M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-128.2M | $-535.2M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-128.2M | $-621.7M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-156.6M | $-484.3M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-156.6M | $-583.6M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 56 hospitals with 80-320 beds
- Same-state prioritization (n=57)
- Comp margins: P25=-17.8% / P50=-10.1% / P75=0.2%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.